Vivian Wu | executive |
Howard W. Robin | executive |
Brian Kotzin | executive |
Jonathan Zalevsky | executive |
Jillian Thomsen | executive |
Chris Shibutani | analyst |
Cheng Li | analyst |
Jialiang Liang | analyst |
Mary Kate Davis | analyst |
Jiayuan Gong | analyst |
Tsan-Yu Hsieh | analyst |
Jiale Song | analyst |
Daina Graybosch | analyst |
Good afternoon, and welcome to the Nektar Therapeutics Second Quarter Financial Results Conference Call. [Operator Instructions] Please note, this event is being recorded.
I would now like to turn the conference over to Vivian Wu from Nektar Investor Relations. Please go ahead.
Thank you, Chad, and good afternoon, everyone.